Drug intelligence / Profile preview

DexSil

Development stage
Unknown
Lead developer
Eytelia
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

DexSil is a line of consumer health products and supplements centered around organic silicon, specifically monomethylsilanetriol (MMST). Developed by the Belgian company Eytelia and distributed in Switzerland by Hygis, DexSil is designed to support connective tissue health. Silicon is a vital trace element that plays a crucial role in the formation and cross-linking of collagen and elastin fibers, which are essential for the structural integrity and elasticity of joints, bones, skin, hair, and nails. The DexSil product range includes oral solutions (often marketed as dietary supplements) and topical gels (often classified as medical devices), which may be enriched with additional ingredients such as glucosamine, chondroitin, or bio-activated nettle (Urtica dioica) to enhance their therapeutic effects on joint mobility and pain relief.

Brand names
DexSilDexSil ForteDexSil Instant GelDexSil Joints
Other names
Organic SiliconMonomethylsilanetriolMMSTBio-Activated Silicon
02

Targets

ELN (Elastin)

Beyond the preview

Go deeper on DexSil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DexSil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call